A

Albert Schweitzer Ziekenhuis | Dordwijk - Cardiology Department

Research site
(Unclaimed)
Location
Albert Schweitzerplaats 25, Dordrecht, Zuid-Holland, Netherlands
Site insights

Top conditions

Coronary Artery Disease (9 trials)

Lymphoma (7 trials)

Crohn Disease (7 trials)

Plasma Cell Cancer (7 trials)

Multiple Myeloma (7 trials)

Top treatments

Apixaban
Carboplatin
Dexamethasone
Guselkumab
Cyclophosphamide
Daratumumab
Nivolumab
Golimumab
DAPT
Ciprofloxacin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

28 of 96
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Enrolling
Polycythemia Vera
Drug: Placebo
Drug: Rusfertide

The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with o...

Enrolling
Type 1 Diabetes Mellitus
Biological: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
Dietary Supplement: Colecalciferol 2000 IU

This study will test the hypothesis that implantation of a subcutaneous implantable cardioverter defibrillator (S-ICD) without performing a defibrill...

Active, not recruiting
Ventricular Arrythmia
Procedure: ommitence of defibrillation testing

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Enrolling
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Drug: Placebo
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative...

Active, not recruiting
Colitis, Ulcerative
Crohn's Disease
Drug: Vedolizumab SC

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo,...

Active, not recruiting
Autologous Stem Cell Transplant
Multiple Myeloma
Drug: Ixazomib Citrate
Drug: Placebo

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Rituximab

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Mirikizumab
Drug: Placebo

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid)...

Active, not recruiting
Cancer-associated Thrombosis
Drug: Apixaban 5 MG

The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel mon...

Enrolling
ST Elevated Myocardial Infarction
Dual Antiplatelet Therapy
Drug: Prasugrel based standard DAPT
Drug: Prasugrel based short DAPT
Locations recently updated

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Abemaciclib
Drug: Standard Adjuvant Endocrine Therapy

The study aims to evaluate a modified antiplatelet therapy associated with Firehawk low-dose rapamycin DES in acute myocardial infarction patients tr...

Active, not recruiting
Coronary Artery Disease
Myocardial Infarction, Acute
Drug: Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)
Drug: Standard DAPT

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Active, not recruiting
Multiple Myeloma
Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

Trial sponsors

Erasmus University logo

Erasmus University (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems